Duration of tachypnoea · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Persistent pulmonary hypertension · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Hyperglycaemia · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Gastrointestinal bleed · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · people with bronchiectasis
1 finding from 1 review
Number of participants improved · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in number of participants improved compared with placebo (low certainty).
1 finding from 1 review
Lung function (spirometry indices) ‐ FVC (in L, end study minus baseline values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ diffusion capacity % predicted (end of study) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ RV % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ TLC % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Exacerbations · people with bronchiectasis
1 finding from 1 review
Pseudomonas aeruginosa (P aeruginosa) colonisation · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in pseudomonas aeruginosa (P aeruginosa) colonisation compared with placebo (low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · people with bronchiectasis
1 finding from 1 review
FVC (% predicted) Change from baseline · people with bronchiectasis
1 finding from 1 review
Worse or unimproved within 5 weeks from randomisation · multiple sclerosis patients with acute exacerbations
Corticosteroids or ACTH probably leads to lower worse or unimproved within 5 weeks from randomisation compared with placebo (moderate certainty).
1 finding from 1 review
Mean disability (EDSS) score—at 1 week after randomisation · multiple sclerosis patients with acute exacerbations
Corticosteroids or ACTH showed no clear difference in mean disability (EDSS) score—at 1 week after randomisation compared with placebo (moderate certainty).
1 finding from 1 review
Participants with new exacerbations during · multiple sclerosis patients with acute exacerbations
It is very uncertain whether corticosteroids or ACTH changes participants with new exacerbations during compared with placebo (very low certainty).
1 finding from 1 review
Incomplete recovery at end of study № of participants: 766 (3 RCTs) · Bell's palsy
Antivirals plus corticosteroids showed no clear difference in incomplete recovery at end of study № of participants: 766 (3 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (low certainty).
1 finding from 1 review
RR 0.81 [0.38, 1.74]
Studies not reported
Low
Motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) · Bell's palsy
Antivirals plus corticosteroids probably leads to lower motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (moderate certainty).
1 finding from 1 review
RR 0.56 [0.36, 0.87]
Studies not reported
Moderate
Adverse events № of participants: 656 (2 RCTs) · Bell's palsy
It is very uncertain whether antivirals plus corticosteroids changes adverse events № of participants: 656 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (very low certainty).
1 finding from 1 review
RR 1.17 [0.81, 1.68]
Studies not reported
Very low